Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss

Share this:
Published: 31 Aug 2018

This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy. Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note. Clinical trial analysis of recombinant drugs for different forms of cancer is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Drug delivery, cancer immunotherapies, biomarker identification, gene therapy, vision loss, age-related macular degeneration, aggressive childhood cancers, bladder cancer



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..